trending Market Intelligence /marketintelligence/en/news-insights/trending/SIiB03E8Q8QpPRYXdoNmJA2 content esgSubNav
In This List

Sienna Biopharmaceuticals' asset sale plan wins nod from US bankruptcy court

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook


Sienna Biopharmaceuticals' asset sale plan wins nod from US bankruptcy court

Sienna Biopharmaceuticals Inc., which previously filed for Chapter 11 bankruptcy protection, said the U.S. Bankruptcy Court for the District of Delaware approved the sale of its assets, including intellectual property, related to its experimental drug SNA-001.

The Westlake Village, Calif.-based biopharmaceutical company it will auction assets related to its experimental hair removal treatment, which uses a topical solution of silver photoparticles, for $1.7 million cash.

Following the court's approval, Sienna has requested the Nasdaq Stock Market to delist its shares from Dec. 13.

In November, the court approved Sienna's proposed bidding procedures.

The biopharmaceutical company, which develops therapies in immunology and inflammation that target select pathways in tissues, has previously said it continues to operate its business under the jurisdiction of the same bankruptcy court and according to the provisions of the bankruptcy code.